Recent Stories

Advertorial

EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money.